Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696817 | 0.84 | EPHX2 (0.56) | EPHX2KMT2A | |
| SCHEMBL3985948 | 0.83 | HRH3 (0.67) | LMNAMAPK1HTTSMN1; SMN2HRH3 | |
| SCHEMBL2616222 | 0.83 | FKBP1A (0.65) | LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30812113 | 0.83 | EPHX2 (0.60) | EPHX2LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL215303 | 0.83 | EPHX2 (0.52) | EPHX2SMN1; SMN2 | |
| SCHEMBL31245991 | 0.82 | EPHX2 (0.59) | EPHX2LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL3579113 | 0.82 | KDM4E (0.55) | EPHX2SMN1; SMN2HRH3KMT2AMEN1 | |
| SCHEMBL2177014 | 0.81 | HRH2 (0.54) | LMNAMAPK1HTTSMN1; SMN2HRH3 | |
| SCHEMBL30696767 | 0.81 | EPHX2 (0.58) | EPHX2 | |
| SCHEMBL23304183 | 0.81 | EPHX2 (0.58) | EPHX2LMNAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | EPHX2 2115/4885LMNA 4821/4885MAPK1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.